This channel includes the latest news, interviews and opinion pieces on all aspects of regenerative medicine from around the world, aiming to keep you up to date with the field and aware of different insights and perspectives.

MSCs can be harvested from several human tissues, or derived from induced pluripotent stem cells (iPSCs), and can differentiate into a range of tissue-specific cells. Various studies have also shown the MSCs, unlike iPSCs, show few oncogenic properties, potentially making them safer as therapeutic agents. Their strong capacity for differentiation also makes MSCs useful as a tool to model disease progression and assess drug efficacy. The spotlight will aim to review the current challenges in the production of MSCs with a focus on consistency, safety and efficacy. We will also look into the clinical applications of MSCs for regenerative medicine and how these therapies are going to evolve and change healthcare in the coming years.

This channel will provide updates on regenerative medicine cell therapies, from their discovery and translation to their manufacture and regulation. Read about the latest news in cell therapy development and discover top tips and techniques for scale-up and manufacture.

Getting a regenerative medicine to the clinic requires it to have a manufacturing process that can be scaled up sufficiently for large-scale production. For cell therapies, manufacturing sites need to meet strict quality and technical capabilities, and the therapies themselves need to be generated in sufficient numbers for clinical application and survive transportation. This channel will look at techniques, technologies and processes that may help support the safe, cost-effective and large-scale production of regenerative medicines